Erratum: Dominant-negative fas mutation is reversed by down-expression of c-FLIP (Cancer Research (2007) 67 (108–115) DOI: 10.1158/0008-5472.CAN-06-1415);Dominant-negative Fas mutation is reversed by down-expression of c-FLIP

Cancer Research

Volumn 67, Issue 1, 2007, Pages 108-115

  Bénéteau, Marie ^a   Daburon, Sophie ^a   Moreau, Jean François ^a   Taupin, Jean Luc ^a   Legembre, Patrick ^a  

^a CNRS Bordeaux Segalen University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; MUTANT PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; DOWN REGULATION; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33846450280     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-19-3174     Document Type: Erratum

References (37)

1. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
2. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995;25: 2303-7.
3. Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003;23:1428-40.
4. Ponton A, Clement MV, Stamenkovic I. The CD95 (APO-1/Fas) receptor activates NF-κB independently of its cytotoxic function. J Biol Chem 1996;271:8991-5.
5. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
6. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 2001;276:20633-40.
7. Inohara N, Koseki T, Hu Y, Chen S, Nunez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci U S A 1997;94:10717-22.
8. Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002;21:3704-14.
9. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2354-7.
10. Kimura M, Matsuzawa A. Autoimmunity in mice bearing lprcg: a novel mutant gene. Int Rev Immunol 1994;11:193-210.
11. Gronbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92:3018-24.
12. Landowski TH, Moscinski L, Burke R, et al. CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma 2001;42:835-46.
13. Drappa J, Vaishnaw AK Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335:1643-9.
14. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268:1347-9.
15. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
16. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-7.
17. Legembre P, Beneteau M, Daburon S, Moreau JF, Taupin JL. Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. J Immunol 2003;171:5659-62.
18. Legembre P, Moreau P, Daburon S, Moreau JF, Taupin JL. Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. Cell Death Differ 2002;9:329-39.
19. Taupin JL, Acres B, Dott K, et al. Immunogenicity of HILDA/LIF either in a soluble or in a membrane anchored form expressed in vivo by recombinant vaccinia viruses. Scand J Immunol 1993;38:293-301.
20. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
21. Hausler P, Papoff G, Eramo A, et al. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur J Immunol 1998;28:57-69.
22. Peter ME, Dhein J, Ehret A, et al. APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Int Immunol 1995;7:1873-7.
23. Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-3.
24. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-20.
25. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98: 194-200.
26. Yanagisawa J, Takahashi M, Kanki H, et al. The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 1997;272:8539-45.
27. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-5.
28. Algeciras-Schimnich A, Shen L, Barnhart BC, et al. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002;22:207-20.
29. Legembre P, Barnhart BC, Zheng L, et al. Induction of apoptosis and activation of NF-κB by CD95 require different signalling thresholds. EMBO Rep 2004;5:1084-9.
30. Legembre P, Barnhart BC, Peter ME. The relevance of NF-κB for CD95 signaling in tumor cells. Cell Cycle 2004; 3:1235-9.
31. Poukkula M, Kaunisto A, Hietakangas V, et al. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 2005;280:27345-55.
32. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006;24:321-52.
33. Martin DA, Zheng L, Siegel RM, et al. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type 1a. Proc Natl Acad Sci U S A 1999;96:4552-7.
34. Micheau O, Tschopp J. Induction of TNF receptor 1-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90.
35. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
36. Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol 2004;5:182-9.
37. Legembre P, Daburon S, Moreau P, et al. Amplification of Fas-mediated apoptosis in type II cells via microdomain recruitment. Mol Cell Biol 2005;25:6811-20.